Frontline Tislelizumab Shows Non-Inferior OS vs Sorafenib in Unresectable HCCSeptember 11th 2022
At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.
LEAP-002 Trial Results Support Use of Lenvatinib Monotherapy in uHCC, Despite Missing Co-Primary End PointsSeptember 10th 2022
Although the combination use of lenvatinib plus pembrolizumab did not induce statistically significant differences in the co-primary end points, the LEAP-002 trial induced the longest seen median overall survival with lenvatinib monotherapy in patients with unresectable HCC.
Roundtable Discussion: Abou-Alfa Evaluates Choice of Therapy for HCC Based on Patient FactorsAugust 25th 2022
During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discussed the case of a patient with hepatocellular carcinoma whose comorbidities impacted the choice of treatment.
Pembrolizumab Plus Lenvatinib Misses Primary End Points in Unresectable HCCAugust 5th 2022
While treatment with pembrolizumab and lenvatinib vs lenvatinib alone seemed to have survival benefit in patients with unresectable hepatocellular carcinoma, the primary end points of the trial were missed.
Combination Therapies Outperform Sorafenib in Hepatocellular CarcinomaJuly 28th 2022
The superiority of the combination regimens for hepatocellular carcinoma treatment was demonstrated in results from the IMbrave150 and HIMALAYA trials, according to Josep M. Llovet, MD, PhD.
Cabozantinib Plus Atezolizumab Improved Progression-Free Survival in Patients with HCC Vs SorafenibJuly 21st 2022
In COSMIC-312, reduction in the risk of disease progression or death was achieved with the combination of cabozantinib Plus atezolizumab compatient with sorafenib in patient with hepatocellular carcinoma.
Clinical Commentary: Addressing Challenges in Unresectable HCC and Adding Lenvatinib to Therapy SequencingJuly 9th 2022
During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, discussed therapeutic sequencing for patients with unresectable hepatocellular carcinoma and the use of lenvatinib versus sorafenib.
Durvalumab Plus Tremelimumab Extends Survival With Tolerable Safety in Liver CancerJuly 6th 2022
Improvement in overall survival has been demonstrated with the combination of durvalumab and tremelimumab in patients with unresectable liver cancer treated in the phase 3 HIMALAYA study.
Considering Treatment for Patients with HCC and Autoimmune DiseaseJuly 1st 2022
During a live virtual event, Daneng Li, MD, discussed the case of a 77-year-old woman with stage IV hepatocellular cancer and a Child-Pugh score of A. This is the first of 2 articles from this event.
Case 1: Systemic Therapy in Combination With or Following TACE/TAREJuly 1st 2022
A brief discussion on the role of systemic therapies in combination with or following TACE/TARE in unresectable hepatocellular carcinoma.
Case 1: A 60-Year-Old With Unresectable Hepatocellular CarcinomaJune 24th 2022
Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.
Finn Reviews Options and Dosing for a Patient With Unresectable HCCJune 21st 2022
During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with hepatocellular cancer with a medical history of Crohn disease, cirrhosis, and variceal bleeding.